Status:
COMPLETED
Establishment of Biomarkers for Fabry Disease
Lead Sponsor:
Ohio State University
Collaborating Sponsors:
Genzyme, a Sanofi Company
Conditions:
Fabry Disease
Eligibility:
All Genders
18+ years
Brief Summary
Fabry disease, an x-linked recessive lysosomal storage disease (LSD) is commonly recognized as a cause of renal failure in involved men and more recently recognized in women too. Women are involved in...
Detailed Description
Specific Aims Specific Aim 1. To demonstrate the specificity and sensitivity of the diagnostic capabilities of a neuroretinal examination which includes slit lamp and fundoscopy, and NRFA for the dia...
Eligibility Criteria
Inclusion
- Fabry patient
- evidence of angiopathy (renal, cardiac, or ocular)
- Patients above the age of 18
Exclusion
- Patients unable or unwilling to provide written informed consent will not be recruited
- Patients who are below the age of 18
- Patients who have not or will not be undergoing Fluorescein angiography
- Allergy to fluorescein
- Pregnant women and fetuses are exclude from the study due to risks related to fluorescein and no direct benefit to the pregnant woman and fetus
Key Trial Info
Start Date :
July 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2014
Estimated Enrollment :
4 Patients enrolled
Trial Details
Trial ID
NCT01165697
Start Date
July 1 2010
End Date
December 1 2014
Last Update
January 13 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Eye and Ear Institute
Columbus, Ohio, United States, 43212